CellSource Co.,Ltd. (4880.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenJPY 327.00

From 52W high−47.04%

Volume72300.00

Market capJPY 6.56B

P/E (TTM)66.6x

P/S (TTM)1.9x

Div yield1.51%

Key dataSep 18, 2026

Open

JPY 327.00

From 52W high

−47.04%

Volume

72300.00

Market cap

JPY 6.56B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

5.0x

P/E (TTM)

66.6x

RSI (14)

43.4

MomentumView details →

1D Return

−0.30%

YTD Return

−19.05%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

66.6x

EV/EBITDA

5.0x

EV/Sales

0.5x

P/S (TTM)

1.9x

P/B (TTM)

1.1x

ProfitabilityView details →

Gross Margin

56.08%

Net Margin

2.36%

EBITDA Margin

9.79%

ROE (TTM)

1.48%

ROA (TTM)

1.28%

Asset Turnover

0.53x

GrowthView details →

Revenue YoY

−7.67%

EPS YoY

+79.30%

FCF YoY

—

Revenue CAGR 3Y

−4.59%

EPS CAGR 3Y

−78.53%

EBITDA YoY

—

MomentumView details →

1D Return

−0.30%

YTD Return

−19.05%

1Y Return

−44.21%

RSI (14)

43.4

vs 50D SMA

−3.36%

vs 200D SMA

−13.24%

Capital & dividendView details →

Debt/Equity

—

Current Ratio

13.95x

Quick Ratio

13.75x

Div Yield

1.51%

Div Rate

JPY 5.00

Div Growth 1Y

+0.00%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

3.72B

Net Income (TTM)

88.00M

Op. CF (TTM)

—

Next earningsDec 10, 2026 →

Latest newsMore news →

CellSource reported Q3 FY2026 cumulative ordinary profit of 174 million yen, up 37.0% year-on-year, and revised its full-year ordinary profit forecast upward from a 210 million yen loss to a 76 million yen profit, while revising its full-year net loss forecast downward from 107 million yen to 124 million yen.13d ago

CellSource and Solaris Bio jointly developed freeze-drying technology for extracellular vesicles including exosomes.20d ago

Similar companies

BrightPath Biotherapeutics Co.,Ltd.4594.T Tsubota Laboratory Incorporated4890.T Chiome Bioscience Inc.4583.T Solasia Pharma K.K.4597.T J-Pharma Co.,Ltd.520A.T PRISM BioLab Co.,LTD206A.T Find similar companies →

Latest newsMore news →

CellSource reported Q3 FY2026 cumulative ordinary profit of 174 million yen, up 37.0% year-on-year, and revised its full-year ordinary profit forecast upward from a 210 million yen loss to a 76 million yen profit, while revising its full-year net loss forecast downward from 107 million yen to 124 million yen.13d ago CellSource and Solaris Bio jointly developed freeze-drying technology for extracellular vesicles including exosomes.20d ago